Durable Disease Control With Atezolizumab Plus Bevacizumab but Limited Post‐Progression Outcomes: A Multicenter Real‐World Study in Advanced Hepatocellular Carcinoma
Atez/Bev provided superior survival and durable tumor control; however, post-progression outcomes remained unsatisfactory, underscoring the need for improved second-line approaches after Atez/Bev failure.
Authors
- Taro Watabe
- Kentaro Fujimoto (ORCID: https://orcid.org/0000-0002-8283-891X)
- Michihisa Moriguchi (ORCID: https://orcid.org/0000-0001-9779-4369)
- Ryohei Yoshino
- Hiroaki Kanzaki (ORCID: https://orcid.org/0000-0002-5039-9166)
- Chihiro Miwa
- Kazufumi Kobayashi (ORCID: https://orcid.org/0000-0002-2604-7208)
- Hidemi Unozawa
- R. Sato
- Sae Yumita
- Jun Kato (ORCID: https://orcid.org/0000-0003-4832-8024)
- Keisuke Koroki (ORCID: https://orcid.org/0000-0002-2345-2611)
- Kazuhisa Asahara
- Makoto Fujiya
- Naoya Kanogawa (ORCID: https://orcid.org/0000-0001-7821-6109)
- T. Aramaki
- Ryo Izai
- Sadahisa Ogasawara (ORCID: https://orcid.org/0000-0002-6540-9064)
- Masanori Inoue
- Midori Sawada
- Teppei Akatsuka
- Kazuo Tsubura
- Keiichi Katayama
- Masayuki Yokoyama
- Takuya Yonemoto
- Shingo Nakamoto
- Shunji Watanabe
- Naoki Morimoto
- Takahiro Tsuchiya
- Masato Nakamura
- Haruka Anzai
Institutions
- Jichi Medical University (JP)
- Chiba University (JP)
- Kyoto Prefectural University of Medicine (JP)
- Shizuoka Cancer Center (JP)
Publication Details
- Journal
- Cancer Medicine
- Published
- 2026-02-01
- DOI
- https://doi.org/10.1002/cam4.71655
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00